Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, today announces final data from the PANTAX phase Ib trial confirming the good safety profile of SCO-101 and showing good signs of efficacy in hard-to-treat pancreatic cancer.
The open-label PANTAX phase Ib international multi-center trial has evaluated Scandion’s lead compound SCO-101 in combination with standard of care chemotherapies gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer. The majority of the 22 enrolled patients in the study were heavily pretreated and, in those patients, no other active treatment options were available. The data documents long survival in patients with metastatic pancreatic cancer.
“We are encouraged by the positive overall survival data for this hard-to-treat refractory patient population, confirming the top-line results presented last year. These promising data supports the continued development of SCO-101”, says Lars Damstrup, Chief Medical Officer of Scandion.
Overall findings include:
• The maximal tolerated dose (MTD) was established at 200 mg SCO-101 and presented at ESMO 2023
• PK data demonstrated that the exposure of SCO-101 was in line with the expectations
• 15 patients were evaluable for response and 1 had a PR resulting in an ORR of 6.7%
• Amongst the 15 evaluable patients CBR was 53% (1 PR and 7 SD)
• Progression-free survival (PFS) was 2.5 months and overall survival (OS) was 9.5 months. Both are in line with historical data for the same patient population
[…]